FARMACOLOGIA

Farmacología • Quimioterápicos antiinfecciosos

Bibliografía − Cheng AC, Turnidge J, Collignon P, Looke D, Barton M, Gottlieb T. Control of fluoroquinolone resistance through successful regulation, Australia. Emerg Infect Dis. 2012; 18(9):1453-60. doi: https://doi.org/10.3201/ eid1809.111515 − Europea Medicines Agency (EMA) [internet]. Amsterdam: EMA; 2024 [citado 25 mar 2024]. Disponible en: https://www.ema.europa.eu/en − Gilbert D, Chambers H, Eliopoulos G, Saag M, Pavia A (eds.). Guía Sanford de Terapéutica Antimicrobiana 2021. 51ª ed. Madrid: Axón; 2022. − Gobernado M, Salavert M, Santos M. Quinolonas en antimicrobianos en medicina. Sociedad Española de Quimioterapia. Barcelona: Prous Science; 1999. − Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, et al. Fluoroquinolones and Cardio vascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis. Drug Saf. 2018; 42:529. doi: https://doi.org/10.1007/s40264-018-0751-2 − Huttner A, Wijma RA, Stewardson AJ, Olearo F, von Dach E, Harbarth S, et al. The pharmacokinetics of nitrofurantoin in healthy female volunteers: a randomized crossover study. J Antimicrob Chemother. 2019; 74(6):1656-61. doi: https://doi.org/10.1093/jac/dkz095 − Lodise T, Corey R, Hooper D, Cammarata S. Safety of Delafloxacin: Focus on Adverse Events of Special Inte rest. Open Forum Infect Dis. 2018; 5:ofy220. doi: https://doi.org/10.1093/ofid/ofy220 − Martínez C. Sulfamidas, quinolonas y antisépticos urinarios. En: Pacheco del Cerro E. Farmacología y práctica de enfermería. Barcelona: Masson; 2000. − McGee EU, Samuel E, Boronea B, Dillard N, Milby MN, Lewis SJ. Quinolone Allergy. Pharmacy (Basel). 2019; 7(3):97. doi: https://doi.org/10.3390/pharmacy7030097 − Medimecum 2023. Guía de terapia farmacológica. 28ª ed. Madrid: Springer Healthcare; 2023. − Mensa J, Soriano A, López-Suñé E, Llinares P, Barberán J, Zboromyrska Y. Guía de terapéutica antimicrobiana 2022. 32ª ed. Madrid: Antares; 2022. − Ministerio de Sanidad. Informe de posicionamiento terapéutico de delafloxacino (Quofenix ® ) para el trata miento de la infección bacteriana aguda de la pie y estructuras relacionadas con la piel (ABSSSI) [internet]. Madrid: Ministerio de Sanidad; 2023 [citado 25 mar 2024]. Disponible en: https://www.aemps.gob.es/medi camentosUsoHumano/informesPublicos/docs/2023/IPT-091-2023-Quofenix.pdf − Ortega Romero M, Soriano A. Efectos adversos de las fluoroquinolonas. Med Integral. 2020; 36(10):396-9. − Partin AW, Dmochowski RR, Kavoussi LR, Peters CA, Wein A (eds.). Campbell Walsh Wein Urology. 12 th ed. Philadelphia: Elsevier; 2020. − Patel K, Goldman JL. Safety Concerns Surrounding Quinolone Use in Children. J Clin Pharmacol. 2016; 56(9):1060-75. doi: https://doi.org/10.1002/jcph.715 − Pham TDM, Ziora ZM, Blaskovich MAT. Quinolone antibiotics. Med. Chem. Commun. 2019; 10:1719-39. doi: https://doi.org/10.1039/C9MD00120D − Scott LJ. Delafloxacin: A review in acute bacterial skin and skin strcutre infections. Drugs. 2020; 80(12):1247 58. doi: https://doi.org/10.1007/s40265-020-01358-0 − Schellack N, Bronkhorst E, Maluleka C, Hunt L, Srinivas P, Grootboom W, et al. Fluoroquinolone-resistant Salmonella typhi infection: a report of two cases in South Africa. J. Infect. Dis. 2017; 33(2):54-6. doi: https:// doi.org/10.1080/23120053.2017.1382089 − Sodhi M, Sheldon CA, Carleton B, Etminan M. Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study. Neurology. 2017; 89(8):792-5. doi: https://doi.org/10.1212/ WNL.0000000000004247 − US Food and Drug Administration (FDA). FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions [internet]. FDA; 2018 [citado 25 mar 2024]. Disponible en: https://www.fda.gov/news-events/press-announcements/fda-updates-warnings-fluoroquinolone-anti biotics-risks-mental-health-and-low-blood-sugar-adverse − Yefet E, Salim R, Chazan B, Akel H, Romano S, Nachum Z. The safety of quinolones in pregnancy. Obstet Gynecol Surv. 2014; 69(11):681-94. doi: https://doi.org/10.1097/OGX.0000000000000122 continuación

702